舌下特异性免疫治疗对过敏性哮喘的临床疗效分析  

Effect of sublingual immunotherapy on patients with allergic asthma

作　　者：孙立英[1] 郭胤仕[1] 王怡玮[1] 许以平[1] 

机构地区：[1]上海交通大学医学院附属仁济医院呼吸科/过敏性疾病诊治中心,上海200127

出　　处：《临床肺科杂志》2011年第6期852-853,共2页Journal of Clinical Pulmonary Medicine

摘　　要：目的探讨舌下特异性免疫治疗(SLIT)对过敏性哮喘的临床疗效。方法对57例舌下含服粉尘螨滴剂治疗的过敏性哮喘患者随访观察26周,比较患者治疗前后的症状评分、视觉模拟评分(VAS)、哮喘控制问卷(ACQ)评分、哮喘控制测试(ACT)评分、呼气峰值流速占正常预计值的百分比(PEF%)及对症治疗药物积分。结果治疗后患者日、夜间哮喘症状评分、VAS评分及对症治疗药物积分均明显降低(P<0.05);PEF%明显升高(P<0.05);ACQ评分及ACT评分均有显著改善(P<0.05)。结论舌下特异性免疫治疗能明显改善过敏性哮喘患者的临床症状及患者自觉症状,减少患者用药量,提高患者的疾病控制水平和生活质量。Objective To evaluate the effect of sublingual immunotherapy on patients with allergic asthma.Methods Fifty seven patients with allergic asthma accepted sublingual immunotherapy and were followed up for 26 weeks.We investigated patients＇ symptom scores,visual analogue scale（VAS）,Asthma Control Questionnaire（ACQ）,asthma Control Test（ACT）,peak expiratory flow（PEF）%and medication scores,so we can assess the effect of sublingual immunotherapy.Results Patients＇day and night asthma symptom scores,VAS and medication scores were significantly decreased（P〈0.05）,while PEF% was significantly higher than before（P〈0.05）,ACQ score and ACT score were significantly improved（P〈0.05）.Conclusions Sublingual immunotherapy can improve symptoms and self-evaluation of patients significantly,it also can reduce the drug usage while improve the level of disease control and quality of life.

关 键 词：舌下特异性免疫治疗 粉尘螨 哮喘 

分 类 号：R562.25[医药卫生—呼吸系统]